Donate

Nurse Education Webinar

Nurse Webinar 3

This webinar will provide an overview of what is indolent lymphoma and discuss the current standard management for patients with follicular lymphoma, mantle cell lymphoma and other subtypes. The webinar will cover the nursing management for the patient with indolent lymphoma, including case studies to reflect on your practice.

Part 1: Indolent lymphoma: overview & the current standard management in Australia

Presented by Professor Chan Cheah, Consultant Haematologist.

Prof Chan Cheah is a Consultant Haematologist, the clinical lead for lymphoma and Clinical Researcher at Sir Charles Gairdner Hospital. He also works at Hollywood Private Hospital and is the Director of Blood Cancer Research WA. Prof Cheah is an internationally renowned expert who has authored over 70 peer-reviewed publications. He is passionate about improving access for Western Australian patients to the novel lymphoma treatments.

Part 2: Nursing management of the patient with indolent lymphoma

Presented by Ron Middleton, Clinical Nurse Consultant.

Ron has been the Haematology Cancer Care Coordinator and Clinical Nurse Consultant at Toowoomba Hospital in regional Queensland since 2013. Ron has been a registered nurse for almost 35 years and has dedicated most of his career to malignant haematology. The majority of Ron’s career has been at the Royal Brisbane & Women’s Hospital, in a number of clinical settings and roles that include haematology, bone marrow transplant unit, education and haematology clinical nurse consultant. Ron has been a lecturer at the Queensland Institute of Technology (QUT) including for the haematology & immunology post graduate course and the Nurse Practitioner course. He has authored a number of peer-reviewed national and international publications.

Support and information

Patient Online Forum

Find Out More

Lymphoma Nurse Support Phone Line: 1800 953 081
Free Resources for you

Find Out More

Lymphoma Nurse Support Email
nurse@lymphoma.org.au

Sign up to our Newsletter

Back to top
Sign Up
About Us
Lymphoma
Patients
Get Involved
Lymphoma Australia is the only incorporated charity in Australia dedicated to solely providing education, support, awareness and advocacy initiatives for Australians touched by lymphoma and chronic lymphocytic leukemia (CLL).
Copyright © 2025. Lymphoma Australia
Linkedin Spotify
Contact Us
Share This
Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.